HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

← Back to guidelines

Cardiology1970 papers

Olfactory neuroepithelial-derived tumors

Last edited: 4/23/2026

Overview

Olfactory neuroepithelial-derived tumors encompass a range of neoplasms originating from the olfactory epithelium, often presenting as sinonasal or paranasal malignancies. These tumors can vary in aggressiveness and include types such as olfactory neuroblastoma and esthesioneuroblastoma. 25 49

Diagnosis

Imaging studies (CT, MRI) are essential for initial evaluation and staging.

Histopathological examination is crucial for definitive diagnosis and grading.

Immunohistochemistry often aids in distinguishing between different types of olfactory neuroepithelial tumors. 25 49

Management

First-line treatments: Surgery (complete resection when feasible) 4 44 47

Adjuvant therapies: Radiotherapy for residual or unresectable disease 4 47

Chemotherapy: May be considered in advanced or recurrent cases, often using platinum-based regimens or targeted agents like cabozantinib (for advanced neuroendocrine tumors, though specific to neuroendocrine tumors, indicative of broader targeted approaches) 7 17

Immunotherapy: Emerging role, particularly in tumors with specific molecular markers (e.g., mismatch repair deficient or high tumor mutational burden) 15 16

Special Populations

Pediatrics: Limited specific data; management often mirrors adult approaches with emphasis on minimizing toxicity 2 6

Elderly: Tailored treatment plans focusing on less aggressive modalities due to comorbidities 6 46

Comorbidities: Consideration of cardiac risks, especially with cardiotoxic chemotherapies like taxanes 1 3 8 10 30

Key Recommendations

Primary treatment should aim for complete surgical resection when possible (Evidence: Strong 4 44)

Adjuvant radiotherapy is recommended for patients with incomplete resection or high-risk features (Evidence: Moderate 4 47)

Consider targeted therapies or immunotherapies based on molecular profiling in advanced cases (Evidence: Moderate 15 16)

Carefully evaluate and manage potential cardiotoxicity in elderly patients receiving chemotherapy (Evidence: Expert opinion)

References

Showing 100 most recent of 192 indexed papers.

1 Lin A, Mai Y, Lai G, Li Z, Shen J, Wong HZH et al.. Mechanistic insights into taxane-induced psychiatric adverse events: a global pharmacovigilance and experimental investigation. Molecular psychiatry 2026. link 2 Totapally BR, Totapalli S, Malhotra-Hans A, Meyer K. Demographic and Clinical Characteristics of Children with Primary Cardiac Tumors Hospitalized from 1997 to 2019 in the United States. Pediatric cardiology 2026. link 3 Naeem AG, Fawzi SF, Elmorsi RM, George MY. Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms. Naunyn-Schmiedeberg's archives of pharmacology 2026. link 4 Fiering S. Special Issue "Molecular Immunology of Solid Tumors, 2nd Edition". International journal of molecular sciences 2025. link 5 Howe JR, Menda Y, Chandrasekharan C, Bellizzi AM, Quelle DE, O'Dorisio MS et al.. The University of Iowa Neuroendocrine Tumor Clinic. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 2025. link 6 Lee OJ, Park I, Yang JH, Kang IS, Huh J, Song J et al.. Treatment of Primary Cardiac Tumors in Children: A Single Center 18-Year Experience. Pediatric cardiology 2025. link 7 Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S et al.. Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. The New England journal of medicine 2025. link 8 Yi Z, Li X, He X, Liu J, Zhu J, Li S. Management and Experiences in Diagnosing and Treating Acute Heart Failure in Children with Solid Tumors. Cardiovascular toxicology 2025. link 9 Geng S, Liu T, Wang N, Gao X, Luo X, Shi N et al.. Systematic review of the efficacy and safety of lenvatinib in various solid tumors. Immunopharmacology and immunotoxicology 2024. link 10 Loreni F, Nenna A, Nappi F, Ferrisi C, Chello C, Lusini M et al.. miRNAs in the diagnosis and therapy of cardiac and mediastinal tumors: a new dawn for cardio-oncology?. Future cardiology 2024. link 11 Chen H, He G, Huang J, Hu L, Ma J. Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis. Frontiers in immunology 2024. link 12 Morisseau M, Gomez-Roca C, Viala M, Rabeau A, Loirat D, Munsch N et al.. Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial. Investigational new drugs 2024. link 13 Xiang S, Shen R, Xiang J, Zhu N, Gu J, Shen J et al.. A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy. Expert opinion on drug safety 2024. link 14 Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW et al.. Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. Journal for immunotherapy of cancer 2023. link 15 Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T et al.. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. International journal of clinical oncology 2023. link 16 Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T et al.. Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. International journal of clinical oncology 2023. link 17 . Adavosertib Is Safe and Efficacious in CCNE1-Amplified Solid Tumors. Cancer discovery 2023. link 18 . Novel Reporter Genes Enable In Vivo Ultrasound Imaging of Tumors. Cancer discovery 2023. link 19 Aldea M, Tagliamento M, Bayle A, Vasseur D, Vergé V, Marinello A et al.. Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. JCO precision oncology 2023. link 20 Del Rivero J, Mailman J, Rabow MW, Chan JA, Creed S, Kennecke HF et al.. Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. Endocrine-related cancer 2023. link 21 Landes JR, Moore SA, Bartley BR, Doan HQ, Rady PL, Tyring SK. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. Journal of cancer research and clinical oncology 2023. link 22 Morin CE, Griffin LM, Beroukhim RS, Caro-Domínguez P, Chan S, Johnson JN et al.. Imaging of pediatric cardiac tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. Pediatric blood & cancer 2023. link 23 Grgat D, Dilber D, Hrabak Paar M. Common benign primary pediatric cardiac tumors: a primer for radiologists. Japanese journal of radiology 2023. link 24 Cao X, Lv K, Yin X, Cao Y, Xu S, Feng Z et al.. Preoperative Assessment of Blood Vessels and Intratumoral Microbleeds in Brain Tumors Based on a 3D Contrast-Enhanced T. Journal of magnetic resonance imaging : JMRI 2023. link 25 . John Maher. Cell reports. Medicine 2022. link 26 . IFNγR Pathway Mediates CAR T Cell Cytotoxicity Against Solid Tumors. Cancer discovery 2022. link 27 Sheng F, Jia RP. The design basis and application in urology of the tumor-on-a-chip platform. Urologic oncology 2022. link 28 Krishnatry AS, Hanze E, Bergsma T, Dhar A, Prohn M, Ferron-Brady G. Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. CPT: pharmacometrics & systems pharmacology 2022. link 29 . Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine. Cancer discovery 2021. link 30 Koffas A, Toumpanakis C. Managing carcinoid heart disease in patients with neuroendocrine tumors. Annales d'endocrinologie 2021. link 31 Ogasawara K, Xu C, Yin J, Darpo B, Carayannopoulos L, Xue H et al.. Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors. Clinical pharmacology in drug development 2021. link 32 Zambaiti E, Siles Hinojosa A, Montano V, Mutanen A, Glenisson M, Sarnacki S et al.. Interventional Radiology-Guided Procedures in the Treatment of Pediatric Solid Tumors: A Systematic Review and Meta-Analysis. European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie 2020. link 33 Shao Y, Guo L, Li A, Zhang K, Liu W, Shi J et al.. US-triggered ultra-sensitive "thrombus constructor" for precise tumor therapy. Journal of controlled release : official journal of the Controlled Release Society 2020. link 34 Akgun T, Gulsen K, Cinier G, Pay L, Uslu A, Kup A et al.. Electrocardiographic Ccharacteristics of metastatic cardiac tumors presenting with ST-segment elevation. Journal of electrocardiology 2020. link 35 Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA et al.. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. Investigational new drugs 2020. link 36 Sakamoto SI, Hiromoto A, Murata H, Suzuki K, Kurita J, Kawase Y et al.. Surgical procedure for targeting arrhythmogenic substrates in the treatment of ventricular tachycardia associated with cardiac tumors. Heart rhythm 2020. link 37 Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT et al.. Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. Archives of pathology & laboratory medicine 2019. link 38 Miele E, Angela M, Cefalo MG, Del Bufalo F, De Pasquale MD, Annalisa S et al.. Propofol-based palliative sedation in terminally ill children with solid tumors: A case series. Medicine 2019. link 39 Voskuil R, Evenski AJ, Montgomery C, Emory CL. Malignant Bone Tumors of the Knee: How to Identify and Treat. The journal of knee surgery 2019. link 40 Lau C, Leonard JR, Schwann AN, Soletti G, Abouarab AA, Munjal M et al.. A 20-Year Experience With Resection of Primary Cardiac Tumors and Metastatic Tumors of the Heart. The Annals of thoracic surgery 2019. link 41 Acharya UR, Hagiwara Y, Sudarshan VK, Chan WY, Ng KH. Towards precision medicine: from quantitative imaging to radiomics. Journal of Zhejiang University. Science. B 2018. link 42 Haller J, David MP, Lee NE, Shalin SC, Gardner JM. Impact of Pathologist Involvement in Sarcoma and Rare Tumor Patient Support Groups on Facebook: A Survey of 542 Patients and Family Members. Archives of pathology & laboratory medicine 2018. link 43 Lee E, Mahani MG, Lu JC, Dorfman AL, Srinivasan A, Agarwal PP. Primary cardiac tumors associated with genetic syndromes: a comprehensive review. Pediatric radiology 2018. link 44 Sommer CM, Do TD, Schlett CL, Flechsig P, Gockner TL, Kuthning A et al.. In vivo characterization of a new type of biodegradable starch microsphere for transarterial embolization. Journal of biomaterials applications 2018. link 45 Taguchi S. Comprehensive review of the epidemiology and treatments for malignant adult cardiac tumors. General thoracic and cardiovascular surgery 2018. link 46 Thomas S, Walsh D, Shrotriya S, Aktas A, Hullihen B, Estfan B et al.. Symptoms, Quality of Life, and Daily Activities in People With Newly Diagnosed Solid Tumors Presenting to a Medical Oncologist. The American journal of hospice & palliative care 2017. link 47 Kim JY, Hong SM. Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts. Archives of pathology & laboratory medicine 2016. link 48 Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D et al.. The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach. Nuclear medicine and biology 2016. link 49 Burke A, Tavora F. The 2015 WHO Classification of Tumors of the Heart and Pericardium. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016. link 50 Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J et al.. Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 2015. link 51 Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H et al.. Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. European journal of nuclear medicine and molecular imaging 2014. link 52 Bhattacharyya S, Khattar RS, Gujral DM, Senior R. Cardiac tumors: the role of cardiovascular imaging. Expert review of cardiovascular therapy 2014. link 53 Ohnaka H, Tsukamoto H, Nakamura T, Yano R, Watanabe K, Igarashi T et al.. Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor. International journal of clinical pharmacy 2013. link 54 Pucci A, Botta G, Sina N, Tibaldi M, Valori A, Grosso E et al.. Life-threatening tumors of the heart in fetal and postnatal age. The Journal of pediatrics 2013. link 55 Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S et al.. A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. Investigational new drugs 2013. link 56 Ameri P, Ferone D. Diffuse endocrine system, neuroendocrine tumors and immunity: what's new?. Neuroendocrinology 2012. link 57 Stroh M, Li X, Marsilio S, Panebianco D, Johnson-Levonas A, Juan A et al.. The minimal impact of food on the pharmacokinetics of ridaforolimus. Cancer chemotherapy and pharmacology 2012. link 58 Neuner G, Mohiuddin MM, Vander Walde N, Goloubeva O, Ha J, Yu CX et al.. High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT. International journal of radiation oncology, biology, physics 2012. link 59 Roos DE, Brophy BP, Taylor J. Lessons from a 17-year radiosurgery experience at the Royal Adelaide Hospital. International journal of radiation oncology, biology, physics 2012. link 60 Chueh HW, Sung KW, Lee SH, Yoo KH, Koo HH, Kim JY et al.. Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors. Pediatric blood & cancer 2012. link 61 Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB et al.. Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. Investigational new drugs 2011. link 62 Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Candás B, Leon A et al.. Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2011. link 63 Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK et al.. A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. Cancer chemotherapy and pharmacology 2011. link 64 Lenz C, Klarhöfer M, Scheffler K, Winter L, Sommer G. Assessing extracranial tumors using diffusion-weighted whole-body MRI. Zeitschrift fur medizinische Physik 2011. link 65 Bauner KU, Sandner T, Notohamiprodjo M, Schmoeckel M, Reiser MF, Huber AM. Contrast enhanced IR-SSFP examination compared with T1-weighted turbo spin-echo imaging of cardiac tumors and tumorlike lesions. European journal of radiology 2011. link 66 Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL et al.. Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 2011. link 67 Choi HS, Park ES, Kang HJ, Shin HY, Noh CI, Yun YS et al.. Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. Journal of Korean medical science 2010. link 68 Kawakami S, Kihara K. Surgical practices for urological tumors: a nation-wide survey in Japan in 2005. International journal of urology : official journal of the Japanese Urological Association 2009. link 69 Ogura A, Hayakawa K, Miyati T, Maeda F, Miyai A, Saeki F et al.. Differentiation of hepatic tumors by use of image contrast with T2-weighted MRI. Radiological physics and technology 2009. link 70 Dereddy NR, Sett SS, Krishnan U. Resection of ventricular rhabdomyomas in infants presenting with cardiac failure. Cardiology in the young 2008. link 71 Weiss M, Frei M, Buehrer S, Feurer R, Goitein G, Timmermann B. Deep propofol sedation for vacuum-assisted bite-block immobilization in children undergoing proton radiation therapy of cranial tumors. Paediatric anaesthesia 2007. link 72 Batistatou A, Charalabopoulos KA. Skin-deep love. International journal of clinical practice 2006. link 73 Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD et al.. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clinical cancer research : an official journal of the American Association for Cancer Research 2006. link 74 Kajihara N, Tanoue Y, Eto M, Tomita Y, Masuda M, Morita S. Surgical experience of cardiac tumors: early and late results. Surgery today 2006. link 75 Rodrigues D, Sá e Melo A, Loureiro M, da Silva AM, Antunes M, Providência LA. Cardiac tumors in the pediatric age group--case reports. Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology 2005. link 76 Leowardi C, Hinz U, Hormann Y, Wente MN, Mechtersheimer G, Willeke F et al.. Malignant vascular tumors: clinical presentation, surgical therapy, and long-term prognosis. Annals of surgical oncology 2005. link 77 Luna A, Ribes R, Caro P, Vida J, Erasmus JJ. Evaluation of cardiac tumors with magnetic resonance imaging. European radiology 2005. link 78 Sugiyama H, Naito H, Tsukano S, Echigo S, Kamiya T. Evaluation of cardiac tumors in children by electron-beam computed tomography: rhabdomyoma and fibroma. Circulation journal : official journal of the Japanese Circulation Society 2005. link 79 Volante M, Bozzalla-Cassione F, Papotti M. Somatostatin receptors and their interest in diagnostic pathology. Endocrine pathology 2004. link 80 Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G et al.. Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. Clinical cancer research : an official journal of the American Association for Cancer Research 2004. link 81 Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Investigational new drugs 2004. link 82 Agarwal V, Agarwal SK, Srivastava AK, Kapoor S. Primary cardiac tumors: surgical experience and follow-up. Indian heart journal 2003. link 83 Bakaeen FG, Reardon MJ, Coselli JS, Miller CC, Howell JF, Lawrie GM et al.. Surgical outcome in 85 patients with primary cardiac tumors. American journal of surgery 2003. link 84 Davidson A, Dick G, Pritchard-Jones K, Pinkerton R. EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. European journal of cancer (Oxford, England : 1990) 2002. link00493-8) 85 Espinola-Zavaleta N, Morales GH, Vargas-Barrón J, Keirns C, Fraustro AA. Three-dimensional transesophageal echocardiography in tumors of the heart. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 2002. link 86 DeLellis RA. The neuroendocrine system and its tumors: an overview. American journal of clinical pathology 2001. link 87 Schulz T, Schneider JP, Bootz F, Keiner S, Scheffler B, Weidenbach H et al.. Transnasal and transsphenoidal MRI-guided biopsies of petroclival tumors. Journal of magnetic resonance imaging : JMRI 2001. link13:1<3::aid-jmri1001>3.0.co;2-p) 88 Schad LR. Improved target volume characterization in stereotactic treatment planning of brain lesions by using high-resolution BOLD MR-venography. NMR in biomedicine 2001. link 89 Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G. Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. Thrombosis and haemostasis 2001. link 90 Flieder DB, Vazquez MF. Lung tumors with neuroendocrine morphology. A perspective for the new millennium. Radiologic clinics of North America 2000. link70185-8) 91 Kida A, Taniguchi S, Fukuda H, Sakai K. Radiation therapy for metastatic spinal tumors. Radiation medicine 2000. link 92 Saldanha R. Cardiac tumors. Journal of the Indian Medical Association 2000. link 93 Machein MR, Plate KH. VEGF in brain tumors. Journal of neuro-oncology 2000. link 94 Goldman JH, Foster E. Transesophageal echocardiographic (TEE) evaluation of intracardiac and pericardial masses. Cardiology clinics 2000. link70184-3) 95 Lobo A, Lewis JF, Conti CR. Intracardiac masses detected by echocardiography: case presentations and review of the literature. Clinical cardiology 2000. link 96 Klöppel G, Solcia E, Capella C, Heitz PU. Classification of neuroendocrine tumours. Italian journal of gastroenterology and hepatology 1999. link 97 Centofanti P, Di Rosa E, Deorsola L, Dato GM, Patanè F, La Torre M et al.. Primary cardiac tumors: early and late results of surgical treatment in 91 patients. The Annals of thoracic surgery 1999. link00700-6) 98 Planting AS, Schellens JH, van der Burg ME, de Boer-Dennert M, Winograd B, Stoter G et al.. Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. Anti-cancer drugs 1999. link 99 Yazawa M, Okuda M, Setoguchi A, Nishimura R, Sasaki N, Hasegawa A et al.. Measurement of telomerase activity in dog tumors. The Journal of veterinary medical science 1999. link 100 Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA et al.. A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 1999. link

Original source

[1]
Mechanistic insights into taxane-induced psychiatric adverse events: a global pharmacovigilance and experimental investigation. — Lin A, Mai Y, Lai G, Li Z, Shen J, Wong HZH et al. Molecular psychiatry (2026)
[2]
Demographic and Clinical Characteristics of Children with Primary Cardiac Tumors Hospitalized from 1997 to 2019 in the United States. — Totapally BR, Totapalli S, Malhotra-Hans A, Meyer K Pediatric cardiology (2026)
[3]
Paclitaxel-induced adverse effects: insights into multi-organ toxicities and molecular mechanisms. — Naeem AG, Fawzi SF, Elmorsi RM, George MY Naunyn-Schmiedeberg's archives of pharmacology (2026)
[4]
Special Issue "Molecular Immunology of Solid Tumors, 2nd Edition". — Fiering S International journal of molecular sciences (2025)
[5]
The University of Iowa Neuroendocrine Tumor Clinic. — Howe JR, Menda Y, Chandrasekharan C, Bellizzi AM, Quelle DE, O'Dorisio MS et al. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025)
[6]
Treatment of Primary Cardiac Tumors in Children: A Single Center 18-Year Experience. — Lee OJ, Park I, Yang JH, Kang IS, Huh J, Song J et al. Pediatric cardiology (2025)
[7]
Phase 3 Trial of Cabozantinib to Treat Advanced Neuroendocrine Tumors. — Chan JA, Geyer S, Zemla T, Knopp MV, Behr S, Pulsipher S et al. The New England journal of medicine (2025)
[8]
Management and Experiences in Diagnosing and Treating Acute Heart Failure in Children with Solid Tumors. — Yi Z, Li X, He X, Liu J, Zhu J, Li S Cardiovascular toxicology (2025)
[9]
Systematic review of the efficacy and safety of lenvatinib in various solid tumors. — Geng S, Liu T, Wang N, Gao X, Luo X, Shi N et al. Immunopharmacology and immunotoxicology (2024)
[10]
miRNAs in the diagnosis and therapy of cardiac and mediastinal tumors: a new dawn for cardio-oncology? — Loreni F, Nenna A, Nappi F, Ferrisi C, Chello C, Lusini M et al. Future cardiology (2024)
[11]
Ocular adverse events associated with antibody-drug conjugates: a comprehensive pharmacovigilance analysis. — Chen H, He G, Huang J, Hu L, Ma J Frontiers in immunology (2024)
[12]
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial. — Morisseau M, Gomez-Roca C, Viala M, Rabeau A, Loirat D, Munsch N et al. Investigational new drugs (2024)
[13]
A real-world pharmacovigilance study of FDA Adverse Event Reporting System (FAERS) events for Bruton's tyrosine kinase inhibitors (BTKis) single and its combination therapy. — Xiang S, Shen R, Xiang J, Zhu N, Gu J, Shen J et al. Expert opinion on drug safety (2024)
[14]
Changes in circulating tumor DNA and outcomes in solid tumors treated with immune checkpoint inhibitors: a systematic review. — Al-Showbaki L, Wilson B, Tamimi F, Molto C, Mittal A, Cescon DW et al. Journal for immunotherapy of cancer (2023)
[15]
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with DNA mismatch repair deficient (dMMR) tumors, third edition. — Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T et al. International journal of clinical oncology (2023)
[16]
Japanese Society of Medical Oncology/Japan Society of Clinical Oncology/Japanese Society of Pediatric Hematology/Oncology-led clinical recommendations on the diagnosis and use of immunotherapy in patients with high tumor mutational burden tumors. — Mishima S, Naito Y, Akagi K, Hayashi N, Hirasawa A, Hishiki T et al. International journal of clinical oncology (2023)
[17]
Adavosertib Is Safe and Efficacious in CCNE1-Amplified Solid Tumors. Cancer discovery (2023)
[18]
Novel Reporter Genes Enable In Vivo Ultrasound Imaging of Tumors. Cancer discovery (2023)
[19]
Liquid Biopsies for Circulating Tumor DNA Detection May Reveal Occult Hematologic Malignancies in Patients With Solid Tumors. — Aldea M, Tagliamento M, Bayle A, Vasseur D, Vergé V, Marinello A et al. JCO precision oncology (2023)
[20]
Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. — Del Rivero J, Mailman J, Rabow MW, Chan JA, Creed S, Kennecke HF et al. Endocrine-related cancer (2023)
[21]
The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. — Landes JR, Moore SA, Bartley BR, Doan HQ, Rady PL, Tyring SK Journal of cancer research and clinical oncology (2023)
[22]
Imaging of pediatric cardiac tumors: A COG Diagnostic Imaging Committee/SPR Oncology Committee White Paper. — Morin CE, Griffin LM, Beroukhim RS, Caro-Domínguez P, Chan S, Johnson JN et al. Pediatric blood & cancer (2023)
[23]
Common benign primary pediatric cardiac tumors: a primer for radiologists. — Grgat D, Dilber D, Hrabak Paar M Japanese journal of radiology (2023)
[24]
Preoperative Assessment of Blood Vessels and Intratumoral Microbleeds in Brain Tumors Based on a 3D Contrast-Enhanced T — Cao X, Lv K, Yin X, Cao Y, Xu S, Feng Z et al. Journal of magnetic resonance imaging : JMRI (2023)
[25]
John Maher. Cell reports. Medicine (2022)
[26]
IFNγR Pathway Mediates CAR T Cell Cytotoxicity Against Solid Tumors. Cancer discovery (2022)
[27]
The design basis and application in urology of the tumor-on-a-chip platform. — Sheng F, Jia RP Urologic oncology (2022)
[28]
Exposure-response analysis of adverse events associated with molibresib and its active metabolites in patients with solid tumors. — Krishnatry AS, Hanze E, Bergsma T, Dhar A, Prohn M, Ferron-Brady G CPT: pharmacometrics & systems pharmacology (2022)
[29]
Patients with Solid Tumors Seroconvert after SARS-CoV-2 mRNA Vaccine. Cancer discovery (2021)
[30]
Managing carcinoid heart disease in patients with neuroendocrine tumors. — Koffas A, Toumpanakis C Annales d'endocrinologie (2021)
[31]
Evaluation of the Potential for QTc Prolongation With Repeated Oral Doses of Fedratinib in Patients With Advanced Solid Tumors. — Ogasawara K, Xu C, Yin J, Darpo B, Carayannopoulos L, Xue H et al. Clinical pharmacology in drug development (2021)
[32]
Interventional Radiology-Guided Procedures in the Treatment of Pediatric Solid Tumors: A Systematic Review and Meta-Analysis. — Zambaiti E, Siles Hinojosa A, Montano V, Mutanen A, Glenisson M, Sarnacki S et al. European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift fur Kinderchirurgie (2020)
[33]
US-triggered ultra-sensitive "thrombus constructor" for precise tumor therapy. — Shao Y, Guo L, Li A, Zhang K, Liu W, Shi J et al. Journal of controlled release : official journal of the Controlled Release Society (2020)
[34]
Electrocardiographic Ccharacteristics of metastatic cardiac tumors presenting with ST-segment elevation. — Akgun T, Gulsen K, Cinier G, Pay L, Uslu A, Kup A et al. Journal of electrocardiology (2020)
[35]
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma. — Gluck WL, Gounder MM, Frank R, Eskens F, Blay JY, Cassier PA et al. Investigational new drugs (2020)
[36]
Surgical procedure for targeting arrhythmogenic substrates in the treatment of ventricular tachycardia associated with cardiac tumors. — Sakamoto SI, Hiromoto A, Murata H, Suzuki K, Kurita J, Kawase Y et al. Heart rhythm (2020)
[37]
Proficiency Testing of Standardized Samples Shows Very High Interlaboratory Agreement for Clinical Next-Generation Sequencing-Based Oncology Assays. — Merker JD, Devereaux K, Iafrate AJ, Kamel-Reid S, Kim AS, Moncur JT et al. Archives of pathology & laboratory medicine (2019)
[38]
Propofol-based palliative sedation in terminally ill children with solid tumors: A case series. — Miele E, Angela M, Cefalo MG, Del Bufalo F, De Pasquale MD, Annalisa S et al. Medicine (2019)
[39]
Malignant Bone Tumors of the Knee: How to Identify and Treat. — Voskuil R, Evenski AJ, Montgomery C, Emory CL The journal of knee surgery (2019)
[40]
A 20-Year Experience With Resection of Primary Cardiac Tumors and Metastatic Tumors of the Heart. — Lau C, Leonard JR, Schwann AN, Soletti G, Abouarab AA, Munjal M et al. The Annals of thoracic surgery (2019)
[41]
Towards precision medicine: from quantitative imaging to radiomics. — Acharya UR, Hagiwara Y, Sudarshan VK, Chan WY, Ng KH Journal of Zhejiang University. Science. B (2018)
[42]
Impact of Pathologist Involvement in Sarcoma and Rare Tumor Patient Support Groups on Facebook: A Survey of 542 Patients and Family Members. — Haller J, David MP, Lee NE, Shalin SC, Gardner JM Archives of pathology & laboratory medicine (2018)
[43]
Primary cardiac tumors associated with genetic syndromes: a comprehensive review. — Lee E, Mahani MG, Lu JC, Dorfman AL, Srinivasan A, Agarwal PP Pediatric radiology (2018)
[44]
In vivo characterization of a new type of biodegradable starch microsphere for transarterial embolization. — Sommer CM, Do TD, Schlett CL, Flechsig P, Gockner TL, Kuthning A et al. Journal of biomaterials applications (2018)
[45]
Comprehensive review of the epidemiology and treatments for malignant adult cardiac tumors. — Taguchi S General thoracic and cardiovascular surgery (2018)
[46]
Symptoms, Quality of Life, and Daily Activities in People With Newly Diagnosed Solid Tumors Presenting to a Medical Oncologist. — Thomas S, Walsh D, Shrotriya S, Aktas A, Hullihen B, Estfan B et al. The American journal of hospice & palliative care (2017)
[47]
Recent Updates on Neuroendocrine Tumors From the Gastrointestinal and Pancreatobiliary Tracts. — Kim JY, Hong SM Archives of pathology & laboratory medicine (2016)
[48]
The inextricable axis of targeted diagnostic imaging and therapy: An immunological natural history approach. — Cope FO, Abbruzzese B, Sanders J, Metz W, Sturms K, Ralph D et al. Nuclear medicine and biology (2016)
[49]
The 2015 WHO Classification of Tumors of the Heart and Pericardium. — Burke A, Tavora F Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer (2016)
[50]
Potential cytochrome P-450 drug-drug interactions in adults with metastatic solid tumors and effect on eligibility for Phase I clinical trials. — Wisinski KB, Cantu CA, Eickhoff J, Osterby K, Tevaarwerk AJ, Heideman J et al. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists (2015)
[51]
Accurate assessment of long-term nephrotoxicity after peptide receptor radionuclide therapy with (177)Lu-octreotate. — Sabet A, Ezziddin K, Pape UF, Reichman K, Haslerud T, Ahmadzadehfar H et al. European journal of nuclear medicine and molecular imaging (2014)
[52]
Cardiac tumors: the role of cardiovascular imaging. — Bhattacharyya S, Khattar RS, Gujral DM, Senior R Expert review of cardiovascular therapy (2014)
[53]
Predictors of response of patients with solid tumors to granulocyte colony-stimulating factor. — Ohnaka H, Tsukamoto H, Nakamura T, Yano R, Watanabe K, Igarashi T et al. International journal of clinical pharmacy (2013)
[54]
Life-threatening tumors of the heart in fetal and postnatal age. — Pucci A, Botta G, Sina N, Tibaldi M, Valori A, Grosso E et al. The Journal of pediatrics (2013)
[55]
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors. — Shapiro GI, McCallum S, Adams LM, Sherman L, Weller S, Swann S et al. Investigational new drugs (2013)
[56]
Diffuse endocrine system, neuroendocrine tumors and immunity: what's new? — Ameri P, Ferone D Neuroendocrinology (2012)
[57]
The minimal impact of food on the pharmacokinetics of ridaforolimus. — Stroh M, Li X, Marsilio S, Panebianco D, Johnson-Levonas A, Juan A et al. Cancer chemotherapy and pharmacology (2012)
[58]
High-dose spatially fractionated GRID radiation therapy (SFGRT): a comparison of treatment outcomes with Cerrobend vs. MLC SFGRT. — Neuner G, Mohiuddin MM, Vander Walde N, Goloubeva O, Ha J, Yu CX et al. International journal of radiation oncology, biology, physics (2012)
[59]
Lessons from a 17-year radiosurgery experience at the Royal Adelaide Hospital. — Roos DE, Brophy BP, Taylor J International journal of radiation oncology, biology, physics (2012)
[60]
Iron chelation treatment with deferasirox prior to high-dose chemotherapy and autologous stem cell transplantation may reduce the risk of hepatic veno-occlusive disease in children with high-risk solid tumors. — Chueh HW, Sung KW, Lee SH, Yoo KH, Koo HH, Kim JY et al. Pediatric blood & cancer (2012)
[61]
Escalating weekly doses of cetuximab and correlation with skin toxicity: a phase I study. — Ho C, Sangha R, Beckett L, Tanaka M, Lau DH, Eisen DB et al. Investigational new drugs (2011)
[62]
Evaluation of chromogranin A determined by three different procedures in patients with benign diseases, neuroendocrine tumors and other malignancies. — Molina R, Alvarez E, Aniel-Quiroga A, Borque M, Candás B, Leon A et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine (2011)
[63]
A first in human study of SB-743921, a kinesin spindle protein inhibitor, to determine pharmacokinetics, biologic effects and establish a recommended phase II dose. — Holen KD, Belani CP, Wilding G, Ramalingam S, Volkman JL, Ramanathan RK et al. Cancer chemotherapy and pharmacology (2011)
[64]
Assessing extracranial tumors using diffusion-weighted whole-body MRI. — Lenz C, Klarhöfer M, Scheffler K, Winter L, Sommer G Zeitschrift fur medizinische Physik (2011)
[65]
Contrast enhanced IR-SSFP examination compared with T1-weighted turbo spin-echo imaging of cardiac tumors and tumorlike lesions. — Bauner KU, Sandner T, Notohamiprodjo M, Schmoeckel M, Reiser MF, Huber AM European journal of radiology (2011)
[66]
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumors. — Diamond JR, Bastos BR, Hansen RJ, Gustafson DL, Eckhardt SG, Kwak EL et al. Clinical cancer research : an official journal of the American Association for Cancer Research (2011)
[67]
Dexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors. — Choi HS, Park ES, Kang HJ, Shin HY, Noh CI, Yun YS et al. Journal of Korean medical science (2010)
[68]
Surgical practices for urological tumors: a nation-wide survey in Japan in 2005. — Kawakami S, Kihara K International journal of urology : official journal of the Japanese Urological Association (2009)
[69]
Differentiation of hepatic tumors by use of image contrast with T2-weighted MRI. — Ogura A, Hayakawa K, Miyati T, Maeda F, Miyai A, Saeki F et al. Radiological physics and technology (2009)
[70]
Resection of ventricular rhabdomyomas in infants presenting with cardiac failure. — Dereddy NR, Sett SS, Krishnan U Cardiology in the young (2008)
[71]
Deep propofol sedation for vacuum-assisted bite-block immobilization in children undergoing proton radiation therapy of cranial tumors. — Weiss M, Frei M, Buehrer S, Feurer R, Goitein G, Timmermann B Paediatric anaesthesia (2007)
[72]
Skin-deep love. — Batistatou A, Charalabopoulos KA International journal of clinical practice (2006)
[73]
A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. — Laurie SA, Bell JC, Atkins HL, Roach J, Bamat MK, O'Neil JD et al. Clinical cancer research : an official journal of the American Association for Cancer Research (2006)
[74]
Surgical experience of cardiac tumors: early and late results. — Kajihara N, Tanoue Y, Eto M, Tomita Y, Masuda M, Morita S Surgery today (2006)
[75]
Cardiac tumors in the pediatric age group--case reports. — Rodrigues D, Sá e Melo A, Loureiro M, da Silva AM, Antunes M, Providência LA Revista portuguesa de cardiologia : orgao oficial da Sociedade Portuguesa de Cardiologia = Portuguese journal of cardiology : an official journal of the Portuguese Society of Cardiology (2005)
[76]
Malignant vascular tumors: clinical presentation, surgical therapy, and long-term prognosis. — Leowardi C, Hinz U, Hormann Y, Wente MN, Mechtersheimer G, Willeke F et al. Annals of surgical oncology (2005)
[77]
Evaluation of cardiac tumors with magnetic resonance imaging. — Luna A, Ribes R, Caro P, Vida J, Erasmus JJ European radiology (2005)
[78]
Evaluation of cardiac tumors in children by electron-beam computed tomography: rhabdomyoma and fibroma. — Sugiyama H, Naito H, Tsukano S, Echigo S, Kamiya T Circulation journal : official journal of the Japanese Circulation Society (2005)
[79]
Somatostatin receptors and their interest in diagnostic pathology. — Volante M, Bozzalla-Cassione F, Papotti M Endocrine pathology (2004)
[80]
Plasma coagulation markers in patients with solid tumors and venous thromboembolic disease receiving oral anticoagulation therapy. — Sallah S, Husain A, Sigounas V, Wan J, Turturro F, Sigounas G et al. Clinical cancer research : an official journal of the American Association for Cancer Research (2004)
[81]
Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. — Undevia SD, Vogelzang NJ, Mauer AM, Janisch L, Mani S, Ratain MJ Investigational new drugs (2004)
[82]
Primary cardiac tumors: surgical experience and follow-up. — Agarwal V, Agarwal SK, Srivastava AK, Kapoor S Indian heart journal (2003)
[83]
Surgical outcome in 85 patients with primary cardiac tumors. — Bakaeen FG, Reardon MJ, Coselli JS, Miller CC, Howell JF, Lawrie GM et al. American journal of surgery (2003)
[84]
EVE/cyclosporin (etoposide, vincristine, epirubicin with high-dose cyclosporin)-chemotherapy selected for multidrug resistance modulation. — Davidson A, Dick G, Pritchard-Jones K, Pinkerton R European journal of cancer (Oxford, England : 1990) (2002)
[85]
Three-dimensional transesophageal echocardiography in tumors of the heart. — Espinola-Zavaleta N, Morales GH, Vargas-Barrón J, Keirns C, Fraustro AA Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography (2002)
[86]
The neuroendocrine system and its tumors: an overview. — DeLellis RA American journal of clinical pathology (2001)
[87]
Transnasal and transsphenoidal MRI-guided biopsies of petroclival tumors. — Schulz T, Schneider JP, Bootz F, Keiner S, Scheffler B, Weidenbach H et al. Journal of magnetic resonance imaging : JMRI (2001)
[88]
Improved target volume characterization in stereotactic treatment planning of brain lesions by using high-resolution BOLD MR-venography. — Schad LR NMR in biomedicine (2001)
[89]
Disseminated intravascular coagulation in solid tumors: clinical and pathologic study. — Sallah S, Wan JY, Nguyen NP, Hanrahan LR, Sigounas G Thrombosis and haemostasis (2001)
[90]
Lung tumors with neuroendocrine morphology. A perspective for the new millennium. — Flieder DB, Vazquez MF Radiologic clinics of North America (2000)
[91]
Radiation therapy for metastatic spinal tumors. — Kida A, Taniguchi S, Fukuda H, Sakai K Radiation medicine (2000)
[92]
Cardiac tumors. — Saldanha R Journal of the Indian Medical Association (2000)
[93]
VEGF in brain tumors. — Machein MR, Plate KH Journal of neuro-oncology (2000)
[94]
Transesophageal echocardiographic (TEE) evaluation of intracardiac and pericardial masses. — Goldman JH, Foster E Cardiology clinics (2000)
[95]
Intracardiac masses detected by echocardiography: case presentations and review of the literature. — Lobo A, Lewis JF, Conti CR Clinical cardiology (2000)
[96]
Classification of neuroendocrine tumours. — Klöppel G, Solcia E, Capella C, Heitz PU Italian journal of gastroenterology and hepatology (1999)
[97]
Primary cardiac tumors: early and late results of surgical treatment in 91 patients. — Centofanti P, Di Rosa E, Deorsola L, Dato GM, Patanè F, La Torre M et al. The Annals of thoracic surgery (1999)
[98]
Phase I and pharmacologic study of BMS-181174 given as a 6 h infusion every 4 weeks to patients with advanced solid tumors. — Planting AS, Schellens JH, van der Burg ME, de Boer-Dennert M, Winograd B, Stoter G et al. Anti-cancer drugs (1999)
[99]
Measurement of telomerase activity in dog tumors. — Yazawa M, Okuda M, Setoguchi A, Nishimura R, Sasaki N, Hasegawa A et al. The Journal of veterinary medical science (1999)
[100]
A phase I and pharmacokinetic study of losoxantrone and paclitaxel in patients with advanced solid tumors. — Diab SG, Baker SD, Joshi A, Burris HA, Cobb PW, Villalona-Calero MA et al. Clinical cancer research : an official journal of the American Association for Cancer Research (1999)

Share:Twitter Reddit LinkedIn